3:02 pm pSivida presents preclinical data demonstrating sustained release of Avastin using Tethadur at ARVO Annual Meeting; says 'we believe the release rate of antibodies loaded into Tethadur can be controlled, which could permit sustained delivery of antibodies that currently must be delivered by frequent injections' (PSDV) :
Co announced that it presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).
pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon". The data from preclinical studies conducted by pSivida concluded that long-term sustained release of antibodies such as Avastin is achievable with Tethadur, a form of pSivida's BioSilicon technology, and that the release of the antibodies is controllable over a wide range by adjusting the pore size and surface area of Tethadur.
"The implications of the ability to control the duration of sustained delivery of antibodies through pore size are significant. By varying pore size, we believe the release rate of antibodies loaded into Tethadur can be controlled, which could permit sustained delivery of antibodies that currently must be delivered by frequent injections